# Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children

> **NCT01613573** · PHASE1 · COMPLETED · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **DRUG:** somatropin AQ
- **DRUG:** pegylated somatropin

## Key facts

- **NCT ID:** NCT01613573
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-10
- **Final completion:** 2010-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01613573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01613573, "Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01613573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*